Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC.
Stivala S, et al. Among authors: buser as.
J Clin Invest. 2019 Mar 4;129(4):1596-1611. doi: 10.1172/JCI98785. eCollection 2019 Mar 4.
J Clin Invest. 2019.
PMID: 30730307
Free PMC article.